<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Based on its potential role in adult <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), the Children's <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (COG) embarked on a phase II study using <z:chebi fb="0" ids="2636">amifostine</z:chebi> in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (WHO 2001 criteria) patients </plain></SENT>
<SENT sid="1" pm="."><plain>Responses were evaluated after two cycles </plain></SENT>
<SENT sid="2" pm="."><plain>Ten patients were enrolled; five were deemed ineligible, and four withdrew after the first course </plain></SENT>
<SENT sid="3" pm="."><plain>Only one patient completed two courses, and was found to be in complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>The study was closed after being open for 2 years due to slow accrual </plain></SENT>
<SENT sid="5" pm="."><plain>Studying a <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may pose insurmountable obstacles even in a large clinical trials group such as COG, in part because of the changing definitions of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and the rarity of adult type <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in children </plain></SENT>
<SENT sid="6" pm="."><plain>The role of <z:chebi fb="0" ids="2636">amifostine</z:chebi> in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was not known at the time of study </plain></SENT>
</text></document>